Dr. Rachel Meyers, Senior Vice President, Research at Alnylam Pharmaceuticals
Dr. Rachel Meyers is Vice President of Research and RNAi Lead Development (RLD) at Alnylam. In this capacity, she plays a key role in the advancement of Alnylam’s RNAi therapeutic programs, from early discovery through clinical development and her team is responsible for program leadership for most of Alnylam’s preclinical and clinical stage programs. In addition to leading the research organization, Dr. Meyers has worked closely with Alnylam’s business development group, playing an integral part in establishing important collaborations, and has functioned as a scientific lead in collaborations with Novartis, Takeda, Isis, Roche and Genzyme. She also led the scientific diligence resulting in Alnylam’s acquisition of the Sirna assets from Merck. Prior to taking on the leadership of the Research and RLD Groups, Dr. Meyers was one of Alnylam’s Research Directors, focusing her efforts on the development of RNAi therapeutics to target infectious diseases, and was the project lead for the company’s RSV program, where she was responsible for advancing ALN-RSV01 from inception, through pre-clinical development and into the clinic. Dr. Meyers was honored by Mass High Tech as one of 10 Women to Watch 2007 and by R & D Directions as one of its Top 20 Scientists 2007. Before joining Alnylam in April of 2003, Dr. Meyers was a Senior Scientist at Millennium Pharmaceuticals (1999-2003) where she was involved in the bioinformatics, molecular and cell biology of target discovery. Dr. Meyers completed her postdoctoral training at Harvard Medical School in the field of signal transduction, and received her Ph.D. from MIT in the field of in vitro transcription. She serves as a Scientific Advisor to Editas Medicine.
– Present (13 years 1 month)
– (5 years)
– (4 years)
– (3 years)